What You Should Know:
– Oshi Health, a virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced it has secured $23M in Series A funding. The round was co-led by Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures with a strategic investment from CVS Health Ventures. Takeda Digital Ventures, which has funded the company since its inception, also participated in the round along with several noteworthy health industry veterans, including athenahealth co-founder Jonathan Bush, Nat Turner and Zach Weinberg of Operator Partners and Flatiron Health, serial healthcare entrepreneur and IBD patient advocate Eric M. Stone, and Russell Glass the CEO of Headspace Health.
– The funds will be used to rapidly scale Oshi Health’s groundbreaking virtual-first, integrated approach to GI care delivery. Oshi Health’s evidence-based, whole-person care protocols can diagnose patients and provide treatment, including often-neglected dietary and psychosocial interventions. The company’s virtual, continuous care model is improving medical outcomes and quality of life for members while lowering costs for employers and healthcare consumers.
GI Health: The Silent Epidemic
Digestive health issues are shockingly prevalent with one in five working-age adults suffering from a diagnosed GI condition, and much more living with undiagnosed or untreated illness. Oshi Health was launched in 2020 to improve the lives of people with gastrointestinal diseases. Oshi Health has redesigned GI care for the modern world, filling the significant gaps in diagnosis and evidence-based therapies that traditional GI practices are not structured or incentivized to provide.
In a transformational and high-touch 3- to 6-month program, an integrated Oshi Health care team will diagnose symptoms, identify triggers and guide patients to achieve lasting symptom relief. Long-term, Oshi Health remains the first line of support when questions arise or symptoms flare, helping avoid ER visits and expensive escalations in medication, testing and procedures.
